Case-Based Review

Cutaneous Melanoma


 

Series Editor: Arthur T. Skarin, MD, FACP, FCCP

Melanoma is the sixth most common cancer in the United States and the leading cause of deaths among all cutaneous malignancies. In 2012, it was estimated that approximately 75,000 individuals were diagnosed with melanoma and more than 9000 died. The incidence of melanoma is rising the fastest among all major malignancies, and the lifetime risk of melanoma among men and women now exceeds 1 in 68, as compared with 1:1500 in 1930.4 The incidence of melanoma is predicted to continue increasing, and there has been no corresponding decrease in mortality. This case-based review summarizes the etiology, risk factors, clinical presentation, and management of cutaneous melanomas, which comprise the majority of melanoma cases. The biology and management for other noncutaneous melanomas (such as mucosal or ocular melanomas) are beyond the scope of this review.

To read the full article in PDF:

Click here

Recommended Reading

Topical tazarotene did not improve response to imiquimod 5% in lentigo maligna
MDedge Hematology and Oncology
Nonmelanoma skin cancer linked to increased fracture risk in postmenopausal women
MDedge Hematology and Oncology
Drugs approved in 2013
MDedge Hematology and Oncology
Consumer Reports: Sunscreen SPF claims largely inaccurate
MDedge Hematology and Oncology
ASCO 2014: Dr. Jeffrey A. Sosman gives his top picks in melanoma research
MDedge Hematology and Oncology
High rate of durable responses to pembrolizumab in metastatic melanoma
MDedge Hematology and Oncology
‘Unprecedented’ overall survival of metastatic melanoma
MDedge Hematology and Oncology
VIDEO: Pembrolizumab may herald new hope in advanced melanoma
MDedge Hematology and Oncology
VIDEO: Advanced melanoma on brink of immunotherapy ‘revolution’
MDedge Hematology and Oncology
VIDEO: Drug combo delivers ‘unprecedented’ metastatic melanoma survival
MDedge Hematology and Oncology